Given these promising preclinical results, the ASO IONIS-SOD1Rx (ISIS 333611 and BIIB067) has been proposed as a therapeutic strategy for SOD1-link ALS and has been clinical tested. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.